Revvity (NYSE:RVTY) Hits New 12-Month High – What’s Next?

Shares of Revvity Inc. (NYSE:RVTY) hit a new 52-week high on Thursday . The company traded as high as $118.34 and last traded at $117.8960, with a volume of 46220 shares changing hands. The stock had previously closed at $117.88.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Sanford C. Bernstein started coverage on shares of Revvity in a research report on Friday, June 26th. They set a “market perform” rating and a $115.00 target price for the company. Wall Street Zen upgraded shares of Revvity from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Stifel Nicolaus dropped their price objective on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Robert W. Baird set a $117.00 price objective on Revvity in a research report on Wednesday, May 6th. Finally, Barclays upped their target price on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Price Performance

The company has a fifty day simple moving average of $108.95 and a two-hundred day simple moving average of $99.96. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The company has a market capitalization of $13.05 billion, a price-to-earnings ratio of 55.75, a P/E/G ratio of 2.11 and a beta of 1.07.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. The business had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Institutional Trading of Revvity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. BlackRock Inc. purchased a new stake in Revvity in the second quarter valued at approximately $852,070,000. Norges Bank purchased a new position in Revvity during the fourth quarter worth approximately $80,382,000. Bank of New York Mellon Corp purchased a new position in Revvity during the second quarter worth approximately $78,766,000. Morgan Stanley boosted its holdings in shares of Revvity by 29.6% in the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after purchasing an additional 650,083 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Revvity by 7.0% in the 4th quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock valued at $789,595,000 after purchasing an additional 533,912 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.